ZA200802310B - Glucuronate salt of a piperazine compound - Google Patents
Glucuronate salt of a piperazine compoundInfo
- Publication number
- ZA200802310B ZA200802310B ZA200802310A ZA200802310A ZA200802310B ZA 200802310 B ZA200802310 B ZA 200802310B ZA 200802310 A ZA200802310 A ZA 200802310A ZA 200802310 A ZA200802310 A ZA 200802310A ZA 200802310 B ZA200802310 B ZA 200802310B
- Authority
- ZA
- South Africa
- Prior art keywords
- piperazine compound
- glucuronate salt
- glucuronate
- salt
- piperazine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71616705P | 2005-09-12 | 2005-09-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200802310B true ZA200802310B (en) | 2008-12-31 |
Family
ID=37603202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200802310A ZA200802310B (en) | 2005-09-12 | 2008-03-11 | Glucuronate salt of a piperazine compound |
Country Status (20)
Country | Link |
---|---|
US (1) | US7595310B2 (ru) |
EP (1) | EP1940830A1 (ru) |
JP (1) | JP2009507921A (ru) |
KR (1) | KR20080045285A (ru) |
CN (1) | CN101287730B (ru) |
AR (1) | AR056506A1 (ru) |
AU (1) | AU2006291058B2 (ru) |
BR (1) | BRPI0615853A2 (ru) |
CA (1) | CA2620755A1 (ru) |
EA (1) | EA014942B1 (ru) |
GT (1) | GT200600414A (ru) |
IL (1) | IL189809A0 (ru) |
MY (1) | MY144782A (ru) |
NO (1) | NO20081809L (ru) |
PE (1) | PE20070433A1 (ru) |
SA (1) | SA06270329B1 (ru) |
TW (1) | TW200800974A (ru) |
UA (1) | UA95922C2 (ru) |
WO (1) | WO2007033191A1 (ru) |
ZA (1) | ZA200802310B (ru) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GT200600416A (es) | 2005-09-12 | 2007-09-20 | Sales salicilato y gentisato de un compuesto de piperazina | |
PE20070523A1 (es) | 2005-09-12 | 2007-06-28 | Wyeth Corp | Formulacion de liberacion sostenida del glucuronato de (8-{4-[3-(5-fluoro-1h-indol-3-il)-propil]-piperazin-1-il}-2-metil-4h-benzo[1,4]oxazin-3-ona |
GT200600414A (es) | 2005-09-12 | 2007-09-20 | Sal de glucuranato de compuesto de piperazine | |
MY148643A (en) | 2007-05-11 | 2013-05-15 | Richter Gedeon Nyrt | Solvate and crystalline forms of carbamoyl-cyclohexane derivatives |
HUP0700353A2 (en) | 2007-05-18 | 2008-12-29 | Richter Gedeon Nyrt | Metabolites of (thio)carbamoyl-cyclohexane derivatives |
US7875610B2 (en) | 2007-12-03 | 2011-01-25 | Richter Gedeon Nyrt. | Pyrimidinyl-piperazines useful as D3/D2 receptor ligands |
JP5774988B2 (ja) | 2008-07-16 | 2015-09-09 | リヒター ゲデオン ニルバーノシャン ミーケデーレスベニュタールシャシャーグ | ドーパミン受容体リガンドからなる製剤処方 |
HU230067B1 (hu) | 2008-12-17 | 2015-06-29 | Richter Gedeon Nyrt | Új piperazin só és eljárás előállítására |
HUP0800766A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Vegyeszet | Process for the preparation of piperazine derivatives |
HUP0800765A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Nyrt | A new process for the preparation of piperazine derivatives and their hydrochloric salts |
WO2014031162A1 (en) | 2012-08-20 | 2014-02-27 | Forest Laboratories Holdings Limited | Crystalline form of carbamoyl-cyclohexane derivatives |
US11274087B2 (en) | 2016-07-08 | 2022-03-15 | Richter Gedeon Nyrt. | Industrial process for the preparation of cariprazine |
US11547707B2 (en) | 2019-04-10 | 2023-01-10 | Richter Gedeon Nyrt. | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4438119A (en) | 1982-12-23 | 1984-03-20 | Mead Johnson & Company | Method for alleviation of extrapyramidal motor disorders |
US4687772A (en) | 1986-10-07 | 1987-08-18 | Bristol-Myers Company | Method for improvement of short term memory |
US4771053A (en) | 1987-03-02 | 1988-09-13 | Bristol-Myers Company | Method for alleviation of primary depressive disorders |
US5162375A (en) | 1988-05-06 | 1992-11-10 | Beecham Group P.L.C. | Treatment of neuronal degeneration with 5HT1A agonists |
US5824680A (en) | 1991-08-31 | 1998-10-20 | Bayer Aktiengesellschaft | Ipsapirone for the treatment of alzheimer's disease by improving memory |
DE4135551A1 (de) | 1991-08-31 | 1993-03-04 | Schering Ag | Verwendung von antagonisten oder partiellen agonisten am 5-ht1a-rezeptor zur behandlung und praevention von kognitiven stoerungen |
US5716960A (en) * | 1995-01-13 | 1998-02-10 | U.S. Bioscience Inc. And Individuals | Crystalline trimetrexate salts and the process for making the same |
SE9900190D0 (sv) | 1999-01-22 | 1999-01-22 | Astra Ab | New compounds |
DE19730989A1 (de) * | 1997-07-18 | 1999-01-21 | Merck Patent Gmbh | Piperazin-Derivate |
DE69819173T2 (de) * | 1997-07-25 | 2004-04-15 | H. Lundbeck A/S | Indole und 2,3-dihydroindolderivate, ihre herstellung und verwendung |
HN1999000146A (es) | 1998-09-21 | 2000-11-11 | Pfizer Prod Inc | Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas. |
KR100634039B1 (ko) * | 1999-08-23 | 2006-10-17 | 솔베이 파마슈티칼스 비. 브이 | 신규한 페닐피페라진 |
PL356605A1 (en) | 2000-01-19 | 2004-06-28 | Akzo Nobel N.V. | Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone |
AR032712A1 (es) * | 2001-02-21 | 2003-11-19 | Solvay Pharm Bv | Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen |
CA2533112A1 (en) | 2003-08-13 | 2005-03-03 | Christopher Hulme | Melanin concentrating hormone receptor antagonist |
CA2550485A1 (en) | 2003-12-18 | 2005-07-07 | Teva Pharmaceutical Industries Ltd. | Polymorphic form b2 of ziprasidone base |
GT200600414A (es) | 2005-09-12 | 2007-09-20 | Sal de glucuranato de compuesto de piperazine | |
GT200600416A (es) * | 2005-09-12 | 2007-09-20 | Sales salicilato y gentisato de un compuesto de piperazina | |
PE20070523A1 (es) | 2005-09-12 | 2007-06-28 | Wyeth Corp | Formulacion de liberacion sostenida del glucuronato de (8-{4-[3-(5-fluoro-1h-indol-3-il)-propil]-piperazin-1-il}-2-metil-4h-benzo[1,4]oxazin-3-ona |
-
2006
- 2006-09-08 GT GT200600414A patent/GT200600414A/es unknown
- 2006-09-11 AR ARP060103944A patent/AR056506A1/es not_active Application Discontinuation
- 2006-09-11 PE PE2006001091A patent/PE20070433A1/es not_active Application Discontinuation
- 2006-09-11 TW TW095133454A patent/TW200800974A/zh unknown
- 2006-09-12 KR KR1020087008818A patent/KR20080045285A/ko not_active Application Discontinuation
- 2006-09-12 CN CN2006800382372A patent/CN101287730B/zh not_active Expired - Fee Related
- 2006-09-12 JP JP2008531254A patent/JP2009507921A/ja active Pending
- 2006-09-12 MY MYPI20080551A patent/MY144782A/en unknown
- 2006-09-12 EA EA200800810A patent/EA014942B1/ru not_active IP Right Cessation
- 2006-09-12 SA SA06270329A patent/SA06270329B1/ar unknown
- 2006-09-12 CA CA002620755A patent/CA2620755A1/en not_active Abandoned
- 2006-09-12 WO PCT/US2006/035517 patent/WO2007033191A1/en active Application Filing
- 2006-09-12 BR BRPI0615853-6A patent/BRPI0615853A2/pt not_active IP Right Cessation
- 2006-09-12 AU AU2006291058A patent/AU2006291058B2/en not_active Ceased
- 2006-09-12 EP EP06803440A patent/EP1940830A1/en not_active Withdrawn
- 2006-09-12 US US11/519,756 patent/US7595310B2/en not_active Expired - Fee Related
- 2006-12-09 UA UAA200804630A patent/UA95922C2/ru unknown
-
2008
- 2008-02-27 IL IL189809A patent/IL189809A0/en unknown
- 2008-03-11 ZA ZA200802310A patent/ZA200802310B/xx unknown
- 2008-04-14 NO NO20081809A patent/NO20081809L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2007033191A1 (en) | 2007-03-22 |
JP2009507921A (ja) | 2009-02-26 |
AU2006291058B2 (en) | 2011-09-08 |
NO20081809L (no) | 2008-04-14 |
EA200800810A1 (ru) | 2008-10-30 |
EP1940830A1 (en) | 2008-07-09 |
PE20070433A1 (es) | 2007-04-24 |
CA2620755A1 (en) | 2007-03-22 |
UA95922C2 (en) | 2011-09-26 |
AU2006291058A1 (en) | 2007-03-22 |
KR20080045285A (ko) | 2008-05-22 |
US20070254876A1 (en) | 2007-11-01 |
BRPI0615853A2 (pt) | 2011-05-31 |
CN101287730A (zh) | 2008-10-15 |
CN101287730B (zh) | 2012-03-07 |
TW200800974A (en) | 2008-01-01 |
SA06270329B1 (ar) | 2010-06-15 |
IL189809A0 (en) | 2008-08-07 |
MY144782A (en) | 2011-11-15 |
EA014942B1 (ru) | 2011-04-29 |
AR056506A1 (es) | 2007-10-10 |
US7595310B2 (en) | 2009-09-29 |
GT200600414A (es) | 2007-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL189809A0 (en) | Glucuronate salt of a piperazine compound | |
GB0504995D0 (en) | Use of a compound | |
IL186023A0 (en) | Crystalline form of a quinolinone-carboxamide compound | |
PL1919907T3 (pl) | Związek heterocykliczny | |
ZA200709051B (en) | Heterocyclic compound | |
IL205071A0 (en) | Azolecarboxamide compound or salt thereof | |
EP2065369A4 (en) | UREA CONNECTION OR SALT THEREOF | |
IL223681A0 (en) | Hydroxybenzoate salts of metanicotine compounds | |
HK1123038A1 (en) | Heterocyclic compounds | |
AP2007004282A0 (en) | Derivatives of A 1-phenyltriazole as antiparasiticagents | |
IL196656A0 (en) | Sulfonamide compound or salt thereof | |
HK1117502A1 (en) | Mono-lysine salts of azole compounds | |
ZA200900208B (en) | Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound | |
HK1120408A1 (en) | Sustained-release formulation comprising a glucuronate salt of a piperazine compound and uses thereof | |
ZA200800142B (en) | Heterocyclic compound | |
GB0506967D0 (en) | Novel crystalline salt | |
EP2042499A4 (en) | SALTS OF MORPHOLINE COMPOUND | |
ZA200800488B (en) | New Salt III | |
GB0522829D0 (en) | Use of a compound | |
HK1162519A1 (en) | Hydroxybenzoate salts of metanicotine compounds |